BACKGROUND AND PURPOSE: Current methods to estimate risk of radiation-induced lung toxicity (RILT) rely on dosimetric parameters. We aimed to improve prognostication by incorporating clinical and cytokine data, and to investigate how these factors may interact with the effect of mean lung dose (MLD) on RILT. MATERIALS AND METHODS: Data from 125 patients treated from 2004 to 2013 with definitive radiotherapy for stages I-III NSCLC on four prospective clinical trials were analyzed. Plasma levels of 30 cytokines were measured pretreatment, and at 2 and 4weeks midtreatment. Penalized logistic regression models based on combinations of MLD, clinical factors, and cytokine levels were developed. Cross-validated estimates of log-likelihood and area under the receiver operating characteristic curve (AUC) were used to assess accuracy. RESULTS: In prognosticating grade 3 or greater RILT by MLD alone, cross-validated log-likelihood and AUC were -28.2 and 0.637, respectively. Incorporating clinical features and baseline cytokine levels increased log-likelihood to -27.6 and AUC to 0.669. Midtreatment cytokine data did not further increase log-likelihood or AUC. Of the 30 cytokines measured, higher levels of 13 decreased the effect of MLD on RILT, corresponding to a lower odds ratio for RILT per Gy MLD, while higher levels of 4 increased the association. CONCLUSIONS: Although the added prognostic benefit from cytokine data in our model was modest, understanding how clinical and biologic factors interact with the MLD-RILT relationship represents a novel framework for understanding and investigating the multiple factors contributing to radiation-induced toxicity.
BACKGROUND AND PURPOSE: Current methods to estimate risk of radiation-induced lung toxicity (RILT) rely on dosimetric parameters. We aimed to improve prognostication by incorporating clinical and cytokine data, and to investigate how these factors may interact with the effect of mean lung dose (MLD) on RILT. MATERIALS AND METHODS: Data from 125 patients treated from 2004 to 2013 with definitive radiotherapy for stages I-III NSCLC on four prospective clinical trials were analyzed. Plasma levels of 30 cytokines were measured pretreatment, and at 2 and 4weeks midtreatment. Penalized logistic regression models based on combinations of MLD, clinical factors, and cytokine levels were developed. Cross-validated estimates of log-likelihood and area under the receiver operating characteristic curve (AUC) were used to assess accuracy. RESULTS: In prognosticating grade 3 or greater RILT by MLD alone, cross-validated log-likelihood and AUC were -28.2 and 0.637, respectively. Incorporating clinical features and baseline cytokine levels increased log-likelihood to -27.6 and AUC to 0.669. Midtreatment cytokine data did not further increase log-likelihood or AUC. Of the 30 cytokines measured, higher levels of 13 decreased the effect of MLD on RILT, corresponding to a lower odds ratio for RILT per GyMLD, while higher levels of 4 increased the association. CONCLUSIONS: Although the added prognostic benefit from cytokine data in our model was modest, understanding how clinical and biologic factors interact with the MLD-RILT relationship represents a novel framework for understanding and investigating the multiple factors contributing to radiation-induced toxicity.
Authors: Yi Luo; Issam El Naqa; Daniel L McShan; Dipankar Ray; Ines Lohse; Martha M Matuszak; Dawn Owen; Shruti Jolly; Theodore S Lawrence; Feng-Ming Spring Kong; Randall K Ten Haken Journal: Radiother Oncol Date: 2017-02-22 Impact factor: 6.280
Authors: Matthew H Stenmark; Xu-Wei Cai; Kerby Shedden; James A Hayman; Shuanghu Yuan; Timothy Ritter; Randall K Ten Haken; Theodore S Lawrence; Feng-Ming Spring Kong Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-01 Impact factor: 7.038
Authors: X L Fu; H Huang; G Bentel; R Clough; R L Jirtle; F M Kong; L B Marks; M S Anscher Journal: Int J Radiat Oncol Biol Phys Date: 2001-07-15 Impact factor: 7.038
Authors: Alena Novakova-Jiresova; Mieke M Van Gameren; Rob P Coppes; Harm H Kampinga; Harry J M Groen Journal: Radiother Oncol Date: 2004-05 Impact factor: 6.280
Authors: Lujun Zhao; Kerby Sheldon; Ming Chen; Moli S Yin; James A Hayman; Gregory P Kalemkerian; Doug Arenberg; Susan E Lyons; Jeffrey L Curtis; Mary Davis; Kemp B Cease; Dean Brenner; Mitchell S Anscher; Theodore S Lawrence; Feng Ming Kong Journal: Lung Cancer Date: 2007-10-01 Impact factor: 5.705